Propanc Biopharma, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended March 31, 2017; financial statements are unaudited and reported in U.S. dollars. Although the request metadata labels this “2016 Q3,” the filing covers the quarter ended March 31, 2017. The company was then named Propanc Health Group Corporation; it changed its name to Propanc Biopharma, Inc. on April 20, 2017.
Business context
Propanc is a development-stage biotechnology company focused on cancer treatments. Its lead candidate, PRP, is a pro-enzyme formulation in preclinical development. The company reported no revenue and said it had no products available for sale or products in clinical trials.
Financial results and liquidity
| Metric | Three months ended March 31 | Nine months ended March 31 |
|---|---|---|
| Revenue | $0 in 2017 and 2016 | $0 in 2017 and 2016 |
| Operating expenses | $1.547 million in 2017; $1.291 million in 2016 | $4.631 million in 2017; $3.442 million in 2016 |
| Operating loss | $1.547 million in 2017; $1.291 million in 2016 | $4.631 million in 2017; $3.442 million in 2016 |
| Net loss | $1.371 million in 2017; $2.152 million in 2016 | $6.234 million in 2017; $6.553 million in 2016 |
| Net loss per share | $0.38 in 2017; $1.05 in 2016 | $1.86 in 2017; $3.90 in 2016 |
For the nine-month period, operating cash use was $1.449 million, compared with $2.205 million a year earlier. Financing provided $1.388 million, primarily from convertible notes ($924,000) and warrant exercises ($464,000). Cash fell from $121,070 at June 30, 2016 to $9,058 at March 31, 2017. No investing cash flow was reported in 2017.
At March 31, current assets were $31,212 and current liabilities were $4.760 million, producing a $4.728 million working capital deficit. Total assets were $44,786 and stockholders’ deficit was $4.715 million. Convertible notes and related accrued interest, net, totaled $2.651 million; embedded conversion-option and warrant derivative liabilities totaled approximately $1.098 million. The filing reports no meaningful operating margin because there was no revenue.
Changes versus comparable periods
- Nine-month operating expenses rose by $1.189 million, mainly as administration expense increased $1.273 million. Management attributed the administration increase primarily to stock-option expense and higher wages and salaries.
- Nine-month research and development expense declined to $714,889 from $806,578; management cited lower nonclinical PRP costs as development progressed toward the clinical stage.
- Nine-month net loss narrowed by $319,000, but the company continued to incur substantial operating losses. Management cited the $306,159 research and development tax credit and changes in noncash derivative and foreign-exchange items as important influences.
- Cash used in operations decreased year over year, while financing cash provided fell from $3.668 million to $1.388 million.
Outlook, risks and unusual items
- Going concern: Management said the losses, cash use, working-capital deficit and accumulated deficit raise substantial doubt about the company’s ability to continue as a going concern for twelve months from the filing date. It stated that available cash was insufficient for obligations over the next twelve months and that additional financing was needed; availability and terms were uncertain.
- Development outlook: The filing says a second GLP-compliant toxicity study was completed, as announced April 27, 2017, and the company intended to pursue a UK clinical trial application, anticipated later in 2017. This was an expectation, not a reported clinical-trial start.
- Financing and dilution: Convertible debt included variable-price conversion terms, in some cases at substantial discounts to recent trading prices, and default rates as high as 18% or 24%. These terms may create significant dilution. The company also extended the Delafield debenture maturity to September 30, 2017. After quarter-end, some Eagle Equities back-end notes became eligible for conversion following note-receivable funding.
- Unusual accounting and results items: Nine-month results included $1.473 million of stock-option expense, $1.836 million of debt-discount amortization, $619,436 of put-premium accretion, a $603,938 gain from changes in derivative fair value, a $143,169 foreign-currency transaction gain and a $306,159 tax benefit. These items affect comparability and do not all represent cash flows.
- Commitments and related parties: The Q-Biologicals manufacturing agreement anticipates payments of $2.5 million to $5.0 million over five years, with most spending expected in the first two years; a $124,158 prepayment was noted. The company also disclosed related-party office rent, director advances and compensation arrangements, including a $250,000 CEO bonus authorized in August 2016.
- Controls and legal matters: Management concluded disclosure controls were ineffective and identified material weaknesses involving the lack of an audit committee financial expert, limited technical accounting expertise and inadequate segregation of duties. The filing reported no material pending or threatened lawsuits.
- Post-quarter changes: On April 20, 2017, the company effected a 1-for-250 reverse stock split and changed its name. The filing says share and per-share data were adjusted retrospectively for the split.
Important facts for investors to verify
- Cash availability, near-term obligations and the company’s ability to obtain financing sufficient to continue operations.
- Outstanding debt balances, maturities, default status, conversion formulas and the potential share dilution from variable-price notes and warrants.
- Whether the planned UK clinical trial application was submitted and what regulatory or development milestones followed the reported toxicity studies.
- The timing and funding of the Q-Biologicals manufacturing commitments, including the nonrefundable prepayment terms.
- Progress in remediating the disclosed internal-control weaknesses and the nature and approval of related-party payments and arrangements.
- Share counts and per-share terms after the reverse split, and reconciliation of the filing’s debt balances and conversion disclosures.